Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms
Cardiff Oncology remains a high-risk, pre-commercial biotechnology firm characterized by a lack of sustainable revenue and a heavy reliance on equity-based financing to fund its clinical pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$0.12+13.0% vs -$0.14 | $171,000+110.0% vs $81,429 |
Q3 2026 Aug 11, 2026 | -$0.14-17.0% vs -$0.12 | $104,000+65.7% vs $62,778 |
Q2 2026 May 14, 2026 | -$0.18-38.5% vs -$0.13 | $41,000-53.7% vs $88,571 |
Q1 2026 Feb 24, 2026 | -$0.11+38.9% vs -$0.18 | $243,000+134.8% vs $103,500 |
Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs.

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology.
Benchmark CRDF against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cardiff Oncology, Inc. (CRDF)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.84 | $64.66M | -1.70 | -13.18% | -6735.24% | -111.78% | — | |
| $66.12 | $10.12B | 97.21 | 87.32% | 11.81% | 17.62% | — | |
| $1.97 | $125.22M | -2.44 | 0.78% | -45.37% | -142.22% | — | |
| $34.42 | $1.18B | -6.64 | -43.89% | -339.67% | -29.31% | — | |
| $33.17 | $6.85B | -13.47 | — | -7173.52% | -63.01% | — | |
| $0.03 | $575.64K | -0.00 | 0.57% | -153.28% | — | — |
Cardiff Oncology, Inc. (CRDF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cardiff Oncology, Inc. (CRDF) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 16, 2026·SEC
Jun 11, 2026·SEC
Get notified when CRDF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cardiff Oncology, Inc. (CRDF) stock FAQ — growth, dividends, profitability & financials explained
Cardiff Oncology, Inc. (CRDF) reported $0.6M in revenue over the trailing twelve months. Revenue was $0.6M in fiscal year 2025.
Cardiff Oncology, Inc. (CRDF) grew revenue by 11.6% over the trailing twelve months, compared with the twelve months before.
No. Cardiff Oncology, Inc. (CRDF) reported a net loss of $37.6M over the trailing twelve months.
Cardiff Oncology, Inc. (CRDF) had a return on equity (ROE) of -111.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Cardiff Oncology, Inc. (CRDF) had negative free cash flow of $39.9M over the trailing twelve months.